Thursday, October 28, 2010

17:00-19:00	Plenary Session & Opening Ceremony
17:00-17:20	Greetings
19:00	Welcome Reception

 

Friday, October 29, 2010 /// Hall A - Epilepsy

  

Session (1)	Epilepsy I
08:30-10:30
08:30-10:30	Debate: Should hormonal therapy be used to treat epilepsy?
09:30-10:30	Debate: Should recently approved antiepileptic drugs (AEDs) be used early in the treatment of epilepsy?
10:30-11:00	Coffee Break
Session (2)	Epilepsy II
11:00-13:00
11:00-12:00	Debate: Does use of generic medications pose risk with regard to seizure control?
12:00-13:00	Debate: Should patients with epilepsy who are depressed be routinly treated with antidepressant medication?
13:00-14:00	Lunch Break
Session (3)	Epilepsy III
14:00-16:00
14:00-15:00	Debate: Do extraneous or internal factors other than hormones trigger seizures (e.g. stress, diet, sleep deprivation, etc)?
15:00-16:00	Debate: Does treatment of status epilepticus significantly impact outcome?
16:00-16:30	Coffee Break
Session (4)	Epilepsy IV
16:30-18:30
16:30-17:00	Lecture: How does epilepsy become intractable?
17:00-17:30	Lecture: Epilepsy and autoimmune disease - Auto anti-VGKC, paraneoplastic antibodies, anti-GAD, etc.
17:30-18:30	New Players in Epilepsy

  

Friday, October 29, 2010 /// Hall B - Stroke

   

Session (5)	Stroke I
08:30-10:30
08:30-09:30	Debate: What is the future of stroke prevention: Polypill or individualized risk factor modification?
09:30-10:30	Debate: Is current advanced neuroimaging sufficient for treating acute ischemic stroke?
10:30-11:00	Coffee Break
Session (6)	Stroke II
11:00-13:00
11:00-12:00	Debate: Should somothrombolysis be used in acute stroke management?
12:00-13:00	Debate: Does stress induce stroke?
13:00-14:00	Lunch Break
Session (7)	Stroke III
14:00-16:00
14:00-15:00	Debate: Is aspirin the most cost-effective anti-aggregant to prevent strokes?
15:00-16:00	Debate: Aspirin resistance: Is it real, clinically relevant, and should it be measured?
16:00-16:30	Coffee Break
Session (8)	Stroke IV
16:30-18:30
16:30-17:30	Debate: Are the current tools sufficient to identify the vulnerable plaque?
17:30-18:30	New Players in Stroke   New anticoagulants for atrial fibrillation Sonothrombolysis Citicoline Cooling SPG stimulation TNK Novel thrombolytics

  

Friday, October 29, 2010 /// Hall C - Parkinson's disease (PD)/Movement disorders (MD)

  

Session (9)	PD/MD I
08:30-10:30
08:30-09:30	Debate: Do we need EMG or sonography for BTX therapy?
09:30-10:30	Debate: Are microelectrode recordings advantageous in surgery for movement disorders or subthalmic nucleus (STN) vs. internal globus pallidus (Gpi) in PD-high frequency stimulation (HFS)?
10:30-11:00	Coffee Break
Session (10)	PD/MD II
11:00-13:00
11:00-12:00	Debate: Can neuroprotection be detected in PD?  Do surrogate markers exist in PD?
12:00-13:00	Debate: Is physical therapy important in PD?
13:00-14:00	Lunch Break
Session (11)	PD/MD III
14:00-16:00
14:00-15:00	Debate: Pathological gambling in PD: Disease related or drug related? Are impulse control disorders a real problem for Parkinson patients?
15:00-16:00	Debate: Evidence-based therapeutic options in essential tremor (ET)? ET is a GABA-ergic disease (Alcohol dependence)
16:00-16:30	Coffee Break
Session (12)	Biomarkers
16:30-18:30
18:00-18:30	New Players in PD

  

Saturday, October 30, 2010 /// Hall A - Multiple Sclerosis

 

Session (13)	MS I
08:30-10:30
08:30-09:30	Debate: Are placebo-controlled clinical trials still ethical/necessary in RRMS?
09:30-10:30	Debate: Will the interferon-beta era in MS treatment end soon?
10:30-11:00	Coffee Break
Session (14)	MS II
11:00-13:00
11:00-12:00	Debate: Should all MS patients be treated with statins?
12:00-13:00	Debate: Are infections key environmental factors in MS?
13:00-14:00	Lunch Break
Session (15)	MS III
14:00-16:00
14:00-15:00	Debate: Should we make our treatment decisions (both attack and long term treatment decisions) based on MRI in people with MS?
15:00-16:00	Debate: Highly active RRMS – highly effective, yet highly risky treatments, which one first: Immunosuppression (mitoxantrone or IV cyclophoshamide) vs. Monoclonal antibody therapies (tysabri – and future drugs such as alemtuzumab and rituximab)
16:00-16:30	Coffee Break
Session (16)	MS IV
16:30-18:30
16:30-17:00	Lecture: The Spectrum of Excessive Daytime Sleepiness and Fatigue in MS: Targeting symptoms by improvement of sleep quality and next day alertness (Circadin)
17:00-17:30	Lecture: Chronic cerebrospinal venous insufficiency (CCSVI) and MS: Uncovered player in the pathogenesis and target for treatment
17:30-18:30	New Players in MS   Cladribine Laquinimod Alemtuzumab Rituximab Fumarate Fingolimod

 

Saturday, October 30, 2010 /// Hall B - Headache / Pain

Session (17)	Headache I
08:30-10:30
08:30-09:30	Debate: Is Tension-Type headache a real entity separate from migraine?
09:30-10:30	Debate: Is botulinum toxin an effective treatment for chronic headache?
10:30-11:00	Coffee Break
Session (18)	Headache II
11:00-13:00
11:00-12:00	Debate: Does the first phase of a migraine attack reside in the cortex?
12:00-13:00	Debate: Is it necessary to treat with triptans early in the attack when the headache is mild?
13:00-14:00	Lunch Break
Session (19)	Headache III
14:00-16:00
14:00-15:00	Debate: Is post traumatic headache is neurological and not a psycho-social- societal disorder?
15:00-16:00	Debate: Will CGRP antagonists be an important addition to the treatment of migraine?
16:00-16:30	Coffee Break
Session (20)	Headache IV
16:30-18:30
16:30-17:30	Debate: Should magnesium be given to every headache patient?
17:30-18:00	Lecture: The pipeline for migraine therapy
18:00-18:30	Lecture: Pathophysiology of migraine

 

Saturday, October 30, 2010 /// Dementia - Hall C

  

Session (21)	Dementia I
08:30-10:30
08:30-09:30	Debate: Is MCI a useful diagnostic concept?
09:30-10:30	Debate: Is Tau more important than amyloid in the pathophysiology of AD?
10:30-11:00	Coffee Break
Session (22)	Dementia II
11:00-13:00
11:00-12:00	Debate: Should ChE-I be initiated as early as possible in the treatment of AD?
12:00-13:00	Debate: Should combination treatment with ChE-I and memantine be started as early as possible?
13:00-14:00	Lunch Break
Session (23)	Dementia III
14:00-16:00
16:00-16:30	Coffee Break
Session (24)	Dementia IV
16:30-18:30
16:30-17:30	Debate: Will amyloid vaccination be useful in the treatment of AD?
17:30-18:30	Debate: Will surrogate markers (Blood, CSF, PET imaging) be increasingly useful in the diagnosis of AD?

  

Sunday, October 31, 2010 /// Hall A - Neuromuscular

  

Session (25)	Neuromuscular I
08:30-10:30
08:30-09:30	Debate: CIDP – IVIg vs. Immunosuppression in long-term treatment
09:30-10:30	Debate: Guillain Barre Syndrome: Re-treat with a second IVIg infusion vs. No evidence for a second Infusion
10:30-11:00	Coffee Break
Session (26)	Neuromuscular II
11:00-13:00
11:00-12:00	Debate: Can rituximab effectively treat myelin-associated glycoprotein (MAG) neuropathies?
12:00-13:00	Debate: Skin biopsy – Is this a useful diagnostic tool for painful neuropathies?

  

Sunday, October 31, 2010 /// Hall B - Rehabilitation

  

Session (27)	Rehabilitation
08:30-10:30
08:30-09:30	Debate: Neuro-epistemology: Randomized controlled trials are the gold standard in neurorehabilitation
09:30-10:30	Debate: Spasticity must be treated
10:30-11:00	Coffee Break
Session (28)	SSNN
11:00-13:00
11:00-12:00	Cluster 1: Quantum mechanics and the brain Quantum brain and self directed neuroplasticity
12:00-13:00	Cluster 2: Present and future in neuroprotection Current status in clinical neuroprotection Future approaches in clinical neuroprotection

13:00-13:30

Poster Awards & Closing Ceremony